Neutralization Patterns and Evolution of Sequential HIV Type 1 Envelope Sequences in HIV Type 1 Subtype B-Infected Drug-Naive Individuals

被引:5
|
作者
Nyambi, Phillipe [1 ]
Burda, Sherri [1 ]
Urbanski, Mateusz [1 ]
Heyndrickx, Leo [2 ]
Janssens, Wouter [2 ]
Vanham, Guido [2 ,3 ]
Nadas, Arthur [4 ]
机构
[1] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[2] Vet Affairs New York Harbor Healthcare Syst, Res Enhancement Award Program, New York, NY 10010 USA
[3] Univ Antwerp, Fac Pharmaceut Vet & Biomed Sci, Dept Biomed Sci, B-2020 Antwerp, Belgium
[4] NYU, Sch Med, Inst Environm Med, New York, NY 10016 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1089/aid.2008.0154
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To design a vaccine that will remain potent against HIV-1, the immunogenic regions in the viral envelope that tend to change as well as those that remain constant over time must be identified. To determine the neutralization profiles of sequential viruses over time and study whether neutralization patterns correlate with sequence evolution, 12 broadly neutralizing plasmas from HIV-1 subtype B-infected individuals were tested for their ability to neutralize sequential primary HIV-1 subtype B viruses from four individuals. Three patterns of neutralization were observed, including a loss of neutralization sensitivity by viruses over time, an increase in neutralization sensitivity by sequential viruses, or a similarity in the sensitivity of sequential viruses to neutralization. Seven to 11 gp160 clones from each sequential virus sample were sequenced and analyzed to identify mutational patterns. Analysis of the envelope sequences of the sequential viruses revealed changes characteristic of the neutralization patterns. Viruses that evolved to become resistant to neutralizing antibodies also evolved with diverse sequences, with most of the changes being due to nonsynonymous mutations occurring in the V1/V2, as well as in the constant regions (C2, C3, C4), the most changes occurring in the C3. Viruses from the patient that evolved to become more sensitive to neutralization exhibited less sequence diversity with fewer nonsynonymous changes that occurred mainly in the V1/V2 region. The V3 region remained constant over time for all the viruses tested. This study demonstrates that as viruses evolve in their host, they either become sensitive or resistant to neutralization by antibodies in heterologous plasma and mutations in different envelope regions account for these changes in their neutralization profiles.
引用
收藏
页码:1507 / 1519
页数:13
相关论文
共 50 条
  • [31] HIV type 1 envelope sequences from seroconverting patients in Barbados
    Roth, WW
    Levett, PN
    Hudson, CP
    Roach, TC
    Womack, C
    Bond, VC
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (16) : 1443 - 1446
  • [32] Coreceptor Usage, Diversity, and Divergence in Drug-Naive and Drug-Exposed Individuals from Malawi, Infected with HIV-1 Subtype C for More Than 20 Years
    Seager, Ishla
    Travers, Simon A.
    Leeson, Michael D.
    Crampin, Amelia C.
    French, Neil
    Glynn, Judith R.
    McCormack, Grace P.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (10) : 975 - 983
  • [33] V3 Sequences and Paired HIV Isolates from 52 Non-Subtype B HIV Type 1-Infected Patients
    Monno, Laura
    Brindicci, Gaetano
    Saracino, Annalisa
    Punzi, Grazia
    Cibelli, Donatella
    Lagioia, Antonella
    Angarano, Gioacchino
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (03) : 365 - 372
  • [34] Genetic diversity and antiretroviral drug resistance among drug-naive HIV type 1 infected patients attending clinics in Kinshasa, Democratic Republic of Congo
    Kamangu, E. N.
    Chatte, A.
    Susin, F.
    Boreux, R.
    Kalala, R. L.
    Mvumbi, G. L.
    De Mol, P.
    Vaira, D.
    Hayette, M. -P.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 : 173 - 173
  • [35] CHANGES IN THE HIV-1 ENVELOPE GENE FROM NON SUBTYPE B HIV-1 INFECTED CHILDREN IN KENYA
    不详
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 43 - 43
  • [36] Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B′ Infected Plasma Donor with Broadly Neutralizing Activity
    Hu, Yuanyuan
    Zou, Sen
    Wang, Zheng
    Liu, Ying
    Ren, Li
    Hao, Yanling
    Sun, Shasha
    Hu, Xintao
    Ruan, Yuhua
    Ma, Liying
    Shao, Yiming
    Hong, Kunxue
    VACCINES, 2021, 9 (04)
  • [37] Envelope Coreceptor Tropism, Drug Resistance, and Viral Evolution Among Subtype C HIV-1-Infected Individuals Receiving Nonsuppressive Antiretroviral Therapy
    Kassaye, Seble
    Johnston, Elizabeth
    McColgan, Bryan
    Kantor, Raini
    Enah, Lynn Z.
    Katzenstein, David
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (01) : 9 - 18
  • [38] Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004
    Pillay, Visva
    Ledwaba, Johanna
    Hunt, Gillian
    Rakgotho, Mpho
    Singh, Beverly
    Makubolo, Lindiwe
    Bennett, Diane E.
    Puren, Adrian
    Morris, Lynn
    ANTIVIRAL THERAPY, 2008, 13 : 101 - 107
  • [39] Primary Antiretroviral Drug Resistance among HIV Type 1-Infected Individuals in Brazil
    Sprinz, Eduardo
    Netto, Eduardo M.
    Lima, Maria Patelli J. S.
    Furtado, Juvenao J. D.
    da Eira, Margareth
    Zajdenverg, Roberto
    Madruga, Jose V.
    Lewi, David S.
    Pedro, Rogerio J.
    Soares, Marcelo A.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (09) : 861 - 867
  • [40] Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals
    Winand, Raf
    Theys, Kristof
    Eusebio, Monica
    Aerts, Jan
    Camacho, Ricardo J.
    Gomes, Perpetua
    Suchard, Marc A.
    Vandamme, Anne-Mieke
    Abecasis, Ana B.
    AIDS, 2015, 29 (15) : 2045 - 2052